Skip to content

Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients

Non-interventional, Prospective Study to Evaluate the Impact of CMV Replication Over Hepatitis C Recurrence in Liver Transplant Recipients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01473849
Acronym
VHENUS
Enrollment
179
Registered
2011-11-17
Start date
2010-05-31
Completion date
2013-04-30
Last updated
2012-12-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cytomegalovirus Infection, Hepatitis C

Keywords

Cytomegalovirus, Liver transplantation, Hepatitis C virus, Patients who underwent first liver transplantation due to hepatopathy caused by HCV,confirmed by detection of HCV RNA previously to transplantation

Brief summary

The relationship between cytomegalovirus infection and recurrence of hepatitis C in liver transplant recipients remains controversial. Although some studies (Teixeira et al., 2000; Singh et al., 2005)have not found an association between recurrence of hepatitis C and CMV infection, studies such as Rosen et al. show that 50% of patients with CMV infection suffered cirrhosis durig follow-up period, while between not-infected patients the rate was 11%. To clarify this question, a non-interventional study will be carried out in order to assess if CMV replication is a risk factor for graft dysfunction in liver transplant recipients.

Interventions

None listed

Sponsors

Roche Farma, S.A
CollaboratorINDUSTRY
Sociedad Española de Trasplante Hepático
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men or women who underwent liver transplantation after hepatopathy caused by HCV, confirmed by pre-transplantation detection of HCV RNA * Age \> 18 years old

Exclusion criteria

* Patients co-infected with HBV or HIV * Patients who show other causes of liver disease

Design outcomes

Primary

MeasureTime frameDescription
Effect of CMV replication over hepatitis C recurrence48 weeks after transplantationviral charge of HCV will be assessed 48 weeks after transplantation

Secondary

MeasureTime frame
Effect of CMV replication over fibrosis in graft after Hepatitis C recurrence after transplantation1 year
Effect of CMV recurrence over graft and patient survival1 year
Relationship between viral charge of CMV and HCV during study period1 year

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026